KalVista Pharmaceuticals, Inc. (KALV)
Market Cap | 254.56M |
Revenue (ttm) | n/a |
Net Income (ttm) | -90.72M |
Shares Out | 34.17M |
EPS (ttm) | -3.57 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 409,110 |
Open | 6.83 |
Previous Close | 6.81 |
Day's Range | 6.83 - 7.46 |
52-Week Range | 4.12 - 17.06 |
Beta | 1.11 |
Analysts | Buy |
Price Target | 19.72 (+164.7%) |
Earnings Date | Mar 9, 2023 |
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $19.72, which is an increase of 164.70% from the latest price.
News

KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate rev...

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commerc...

Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 155.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock
KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term...

Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted two ne...

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comme...

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ...

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
CAMBRIDGE, Mass.

KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
CAMBRIDGE, Mass.

KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D.
CAMBRIDGE, Mass.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV
NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of KalVista Pharmaceuticals, Inc. (""KalVista" or the "Company") (NASDAQ: KALV). Such investors ar...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALV
New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of KalVista Pharmaceuticals, Inc. (""KalVista" or the "Company") (NASDAQ: KALV). S...

KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm...

KalVista (KALV) Stock Continues to Decline: Here's Why
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?
KalVista Pharmaceuticals (NASDAQ: KALV) is trending on popular financial social media right now, but it's not good news. Reportedly, there were safety-related concerns over KalVista's clinical study ...